tiprankstipranks
Beam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing
PremiumMarket NewsBeam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing
28d ago
Citi sees limited readthrough for Beam Therapeutics from VERVE-101 trial pause
PremiumThe Fly
Citi sees limited readthrough for Beam Therapeutics from VERVE-101 trial pause
2M ago
Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game?
PremiumStock Analysis & Ideas
Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game?
2M ago
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
PremiumPress ReleasesBeam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
3M ago
Beam Therapeutics files automatic mixed securities shelf
PremiumThe Fly
Beam Therapeutics files automatic mixed securities shelf
3M ago
Beam Therapeutics price target raised to $42 from $26 at Barclays
PremiumThe Fly
Beam Therapeutics price target raised to $42 from $26 at Barclays
3M ago
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
PremiumThe FlyCantor Fitzgerald biotech analysts hold an analyst/industry conference call
4M ago
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
PremiumThe Fly
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
4M ago
Beam Therapeutics upgraded to Overweight from Neutral at JPMorgan
PremiumThe Fly
Beam Therapeutics upgraded to Overweight from Neutral at JPMorgan
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100